Squamous Cell Carcinoma

View All

skin-cancer-treatment-market-and-key-companies
Key Pharma Companies Expanding their Arm in the Skin Cancer Segment

Cancer today is one of the most deadly diseases worldwide, causing a significant burden in terms of mortality, years of life lost, and disability as compared to other diseases. It hampers economic development, weighs down the healthcare system of the country, and affects the quality of life of the patient and their...

Find More

Cutaneous Squamous Cell Carcinoma Market & pipeline

Non-melanoma skin cancer is a group of cancers of the skin and is broadly classified into Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). It has the greatest prevalence in the United States, which can be seen through statistics which show that basal cell carcinoma accounts for 80% while Squamous cell c...

Find More

Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug

Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...

Find More